• Explore /
  • Poster
  • / A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

Abstract Poster

Authors

null

Nicholas James Short

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Nicholas James Short , Hagop M. Kantarjian , Farhad Ravandi , Musa Yilmaz , Tapan M. Kadia , Philip A. Thompson , Marina Konopleva , Alessandra Ferrajoli , Nitin Jain , Koji Sasaki , Yesid Alvarado Valero , Gautam Borthakur , Courtney Denton Dinardo , Maro Ohanian , Walid Macaron , Rebecca Garris , Min Zhao , Monica Kwari , Christopher Loiselle , Elias Jabbour

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01371630

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7034)

DOI

10.1200/JCO.2022.40.16_suppl.7034

Abstract #

7034

Poster Bd #

265

Abstract Disclosures

Similar Posters

First Author: Nicholas James Short

First Author: Rita Assi

First Author: Nicholas James Short

First Author: Ghayas C. Issa